197 related articles for article (PubMed ID: 8614853)
41. Cost effectiveness and other assessments of adjuvant therapies for early breast cancer.
Hillner BE; Smith TJ
Oncology (Williston Park); 1995 Nov; 9(11 Suppl):129-34. PubMed ID: 8608043
[TBL] [Abstract][Full Text] [Related]
42. Economic evaluation of health services. Concepts and methodology applied to screening programmes.
Griffiths DA
Rev Epidemiol Sante Publique; 1981; 29(1):85-101. PubMed ID: 6789412
[TBL] [Abstract][Full Text] [Related]
43. Health and medical economics applied to integrative medicine.
Pelletier KR; Herman PM; Metz RD; Nelson CF
Explore (NY); 2010; 6(2):86-99. PubMed ID: 20362266
[TBL] [Abstract][Full Text] [Related]
44. Time-dependent resource use and costs associated with different states of disease in patients diagnosed with HER-2-positive metastatic breast cancer.
Frederix GW; Severens JL; Hövels AM; van Hasselt JG; Raaijmakers JA; Schellens JH
Breast Cancer Res Treat; 2013 Jun; 139(2):489-95. PubMed ID: 23645005
[TBL] [Abstract][Full Text] [Related]
45. Benefit-cost and cost-effectiveness analysis: theory and application.
McCarthy NJ
Dev Biol Stand; 1979; 43():403-17. PubMed ID: 118068
[TBL] [Abstract][Full Text] [Related]
46. What does breast cancer treatment cost and what is it worth?
Hassett MJ; Elkin EB
Hematol Oncol Clin North Am; 2013 Aug; 27(4):829-41, ix. PubMed ID: 23915747
[TBL] [Abstract][Full Text] [Related]
47. Economic evaluation of docetaxel for breast cancer.
Lwin Z; Leighl N
Expert Opin Pharmacother; 2009 Feb; 10(2):283-90. PubMed ID: 19236199
[TBL] [Abstract][Full Text] [Related]
48. [Economic analyses of health care. Cost benefit analyses promote better use of resources].
Kristiansen IS
Tidsskr Nor Laegeforen; 1990 Aug; 110(18):2377-81. PubMed ID: 2120789
[TBL] [Abstract][Full Text] [Related]
49. Hypofractionated breast radiotherapy: financial and economic consequences.
Lievens Y
Breast; 2010 Jun; 19(3):192-7. PubMed ID: 20511069
[TBL] [Abstract][Full Text] [Related]
50. [Analysis of cost effectiveness of photodynamic therapy with Foscan (Foscan-PDT) in comparison with palliative chemotherapy in patients with advanced head-neck tumors in Germany].
Kübler A; Niziol C; Sidhu M; Dünne A; Werner JA
Laryngorhinootologie; 2005 Oct; 84(10):725-32. PubMed ID: 16231239
[TBL] [Abstract][Full Text] [Related]
51. [Standard treatment cost of female breast cancer at different TNM stages].
Li H; Huang Y; Huang R; Li JY
Zhonghua Zhong Liu Za Zhi; 2013 Dec; 35(12):946-50. PubMed ID: 24506967
[TBL] [Abstract][Full Text] [Related]
52. [Cost aspects of oncologic chemotherapy].
Knüsli C; Obrecht JP
Schweiz Rundsch Med Prax; 1989 May; 78(18):515-9. PubMed ID: 2471245
[TBL] [Abstract][Full Text] [Related]
53. Assessing the cost effectiveness of adjuvant therapies in early breast cancer using a decision analysis model.
Hillner BE; Smith TJ; Desch CE
Breast Cancer Res Treat; 1993; 25(2):97-105. PubMed ID: 8347850
[TBL] [Abstract][Full Text] [Related]
54. Review of cost-effectiveness assessments of chemotherapy in adjuvant and advanced breast cancer.
Hillner BE
Anticancer Drugs; 1998 Nov; 9(10):843-7. PubMed ID: 9890695
[TBL] [Abstract][Full Text] [Related]
55. [Stages in prevention of breast neoplasms. Organization of standard computerized operative programs: preliminary prospective study].
Asteria CR; Bonera A; Di Giovanni M; Scheda RG
Minerva Med; 1984 Dec; 75(47-48):2809-14. PubMed ID: 6441130
[TBL] [Abstract][Full Text] [Related]
56. Outcome and Cost Effectiveness of Ultrasonographically Guided Surgical Clip Placement for Tumor Localization in Patients undergoing Neo-adjuvant Chemotherapy for Breast Cancer.
Masroor I; Zeeshan S; Afzal S; Sufian SN; Ali M; Khan S; Ahmad K
Asian Pac J Cancer Prev; 2015; 16(18):8339-43. PubMed ID: 26745082
[TBL] [Abstract][Full Text] [Related]
57. Systemic therapy in breast cancer: efficacy and cost utility.
Corry JF; Lønning PE
Pharmacoeconomics; 1994 Mar; 5(3):198-212. PubMed ID: 10146895
[TBL] [Abstract][Full Text] [Related]
58. Role of ovarian ablation for premenopausal patients in adjuvant systemic therapy of breast cancer.
Harder H
Trop Doct; 1996 Apr; 26(2):85. PubMed ID: 8685977
[No Abstract] [Full Text] [Related]
59. The relationship between quality and cost during the perioperative breast cancer episode of care.
Landercasper J; Tafra L
Breast; 2010 Aug; 19(4):289-96. PubMed ID: 20382531
[TBL] [Abstract][Full Text] [Related]
60. Canada's Population Health Model (POHEM): a tool for performing economic evaluations of cancer control interventions.
Will BP; Berthelot JM; Nobrega KM; Flanagan W; Evans WK
Eur J Cancer; 2001 Sep; 37(14):1797-804. PubMed ID: 11549434
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
